Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 148

1.

Genetic influences on cognition in progressive supranuclear palsy.

Gerstenecker A, Roberson ED, Schellenberg GD, Standaert DG, Shprecher DR, Kluger BM, Litvan I.

Mov Disord. 2017 Dec;32(12):1764-1771. doi: 10.1002/mds.27196. Epub 2017 Oct 27.

2.

Cognitive impairment in progressive supranuclear palsy is associated with tau burden.

Koga S, Parks A, Kasanuki K, Sanchez-Contreras M, Baker MC, Josephs KA, Ahlskog JE, Uitti RJ, Graff-Radford N, van Gerpen JA, Wszolek ZK, Rademakers R, Dickson DW.

Mov Disord. 2017 Dec;32(12):1772-1779. doi: 10.1002/mds.27198. Epub 2017 Oct 30.

3.

Assessment of common variability and expression quantitative trait loci for genome-wide associations for progressive supranuclear palsy.

Ferrari R, Ryten M, Simone R, Trabzuni D, Nicolaou N, Hondhamuni G, Ramasamy A, Vandrovcova J; UK Brain Expression Consortium, Weale ME, Lees AJ, Momeni P, Hardy J, de Silva R.

Neurobiol Aging. 2014 Jun;35(6):1514.e1-12. doi: 10.1016/j.neurobiolaging.2014.01.010. Epub 2014 Jan 13. Erratum in: Neurobiol Aging. 2015 Nov;36(11):3118. Nicolaou, Naiya [Corrected to Nicolaou, Nayia]. Neurobiol Aging. 2015 Nov;36(11):3118.

4.

Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy.

Kouri N, Ross OA, Dombroski B, Younkin CS, Serie DJ, Soto-Ortolaza A, Baker M, Finch NCA, Yoon H, Kim J, Fujioka S, McLean CA, Ghetti B, Spina S, Cantwell LB, Farlow MR, Grafman J, Huey ED, Ryung Han M, Beecher S, Geller ET, Kretzschmar HA, Roeber S, Gearing M, Juncos JL, Vonsattel JPG, Van Deerlin VM, Grossman M, Hurtig HI, Gross RG, Arnold SE, Trojanowski JQ, Lee VM, Wenning GK, White CL, Höglinger GU, Müller U, Devlin B, Golbe LI, Crook J, Parisi JE, Boeve BF, Josephs KA, Wszolek ZK, Uitti RJ, Graff-Radford NR, Litvan I, Younkin SG, Wang LS, Ertekin-Taner N, Rademakers R, Hakonarsen H, Schellenberg GD, Dickson DW.

Nat Commun. 2015 Jun 16;6:7247. doi: 10.1038/ncomms8247.

5.

The PSP-associated MAPT H1 subhaplotype in Guadeloupean atypical parkinsonism.

Camuzat A, Romana M, Dürr A, Feingold J, Brice A, Ruberg M, Lannuzel A.

Mov Disord. 2008 Dec 15;23(16):2384-91. doi: 10.1002/mds.22297.

PMID:
18785640
6.

Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy.

Brown RG, Lacomblez L, Landwehrmeyer BG, Bak T, Uttner I, Dubois B, Agid Y, Ludolph A, Bensimon G, Payan C, Leigh NP; NNIPPS Study Group.

Brain. 2010 Aug;133(Pt 8):2382-93. doi: 10.1093/brain/awq158. Epub 2010 Jun 24.

PMID:
20576697
7.

The tau gene A0 polymorphism in progressive supranuclear palsy and related neurodegenerative diseases.

Morris HR, Janssen JC, Bandmann O, Daniel SE, Rossor MN, Lees AJ, Wood NW.

J Neurol Neurosurg Psychiatry. 1999 May;66(5):665-7.

8.

Genome-wide association study identifies MAPT locus influencing human plasma tau levels.

Chen J, Yu JT, Wojta K, Wang HF, Zetterberg H, Blennow K, Yokoyama JS, Weiner MW, Kramer JH, Rosen H, Miller BL, Coppola G, Boxer AL; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2017 Feb 14;88(7):669-676. doi: 10.1212/WNL.0000000000003615. Epub 2017 Jan 18.

9.

Different MAPT haplotypes are associated with Parkinson's disease and progressive supranuclear palsy.

Ezquerra M, Pastor P, Gaig C, Vidal-Taboada JM, Cruchaga C, Muñoz E, Martí MJ, Valldeoriola F, Aguilar M, Calopa M, Hernandez-Vara J, Tolosa E.

Neurobiol Aging. 2011 Mar;32(3):547.e11-6. doi: 10.1016/j.neurobiolaging.2009.09.011. Epub 2009 Oct 29.

PMID:
19879020
10.

An R5L tau mutation in a subject with a progressive supranuclear palsy phenotype.

Poorkaj P, Muma NA, Zhukareva V, Cochran EJ, Shannon KM, Hurtig H, Koller WC, Bird TD, Trojanowski JQ, Lee VM, Schellenberg GD.

Ann Neurol. 2002 Oct;52(4):511-6.

PMID:
12325083
11.

Effect of ApoE and tau on age of onset of progressive supranuclear palsy and multiple system atrophy.

Morris HR, Schrag A, Nath U, Burn D, Quinn NP, Daniel S, Wood NW, Lees AJ.

Neurosci Lett. 2001 Oct 19;312(2):118-20.

PMID:
11595348
12.

Regional expression of the MAPT gene is associated with loss of hubs in brain networks and cognitive impairment in Parkinson disease and progressive supranuclear palsy.

Rittman T, Rubinov M, Vértes PE, Patel AX, Ginestet CE, Ghosh BCP, Barker RA, Spillantini MG, Bullmore ET, Rowe JB.

Neurobiol Aging. 2016 Dec;48:153-160. doi: 10.1016/j.neurobiolaging.2016.09.001. Epub 2016 Sep 9.

13.

Clinical and cognitive correlations of regional gray matter atrophy in progressive supranuclear palsy.

Giordano A, Tessitore A, Corbo D, Cirillo G, de Micco R, Russo A, Liguori S, Cirillo M, Esposito F, Tedeschi G.

Parkinsonism Relat Disord. 2013 Jun;19(6):590-4. doi: 10.1016/j.parkreldis.2013.02.005. Epub 2013 Mar 7.

PMID:
23477861
14.

Executive dysfunction is the primary cognitive impairment in progressive supranuclear palsy.

Gerstenecker A, Mast B, Duff K, Ferman TJ, Litvan I; ENGENE-PSP Study Group.

Arch Clin Neuropsychol. 2013 Mar;28(2):104-13. doi: 10.1093/arclin/acs098. Epub 2012 Nov 4.

15.

Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration.

Pittman AM, Myers AJ, Abou-Sleiman P, Fung HC, Kaleem M, Marlowe L, Duckworth J, Leung D, Williams D, Kilford L, Thomas N, Morris CM, Dickson D, Wood NW, Hardy J, Lees AJ, de Silva R.

J Med Genet. 2005 Nov;42(11):837-46. Epub 2005 Mar 25.

16.

Gene expression, methylation and neuropathology correlations at progressive supranuclear palsy risk loci.

Allen M, Burgess JD, Ballard T, Serie D, Wang X, Younkin CS, Sun Z, Kouri N, Baheti S, Wang C, Carrasquillo MM, Nguyen T, Lincoln S, Malphrus K, Murray M, Golde TE, Price ND, Younkin SG, Schellenberg GD, Asmann Y, Ordog T, Crook J, Dickson D, Ertekin-Taner N.

Acta Neuropathol. 2016 Aug;132(2):197-211. doi: 10.1007/s00401-016-1576-7. Epub 2016 Apr 26.

17.

Genetic bases of Progressive Supranuclear Palsy: the MAPT tau disease.

Borroni B, Agosti C, Magnani E, Di Luca M, Padovani A.

Curr Med Chem. 2011;18(17):2655-60. Review.

PMID:
21568901
18.

Progressive supranuclear palsy: pathology and genetics.

Dickson DW, Rademakers R, Hutton ML.

Brain Pathol. 2007 Jan;17(1):74-82. Review.

PMID:
17493041
19.

Genetics of Progressive Supranuclear Palsy.

Im SY, Kim YE, Kim YJ.

J Mov Disord. 2015 Sep;8(3):122-9. doi: 10.14802/jmd.15033. Epub 2015 Sep 10. Review.

20.

Managing cognition in progressive supranuclear palsy.

Rittman T, Coyle-Gilchrist IT, Rowe JB.

Neurodegener Dis Manag. 2016 Dec;6(6):499-508. Epub 2016 Nov 23. Review.

Supplemental Content

Support Center